Kezar Life Sciences Inc

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel small molecule therapeutics for unmet needs in immune-mediated diseases in the United States. Its lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor being studied in indications including lupus nephritis, dermatomyositis, and polymyositis, as well as in Phase 1b/2 clinical trials in systemic lupus erythematosus. The company was incorporated in 2015 and is headquartered in South San Francisco, California.